21.32
-0.84%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China National Accord Medicines Corp
Its shares trade on Shenzhen under the ticker 000028.SZ. It has been listed since 9 August 1993. In the fiscal year to 31 December 2025, it reported revenue of CN¥73.42bn and net income of CN¥1.14bn. At that date it held total assets of CN¥49.10bn and shareholders' equity of CN¥18.61bn.
China National Accord Medicines Corp. Ltd. engages in the research, development, and consultation services of pharmaceutical packaging materials and pharmaceutical industry products. The company is headquartered in Shenzhen, Guangdong. The firm's main products include antibiotic preparations, power injections, antibiotic Active Pharmaceutical Ingredients (APIs), respiratory system drugs and cardiovascular and cerebrovascular system drugs, among others. The firm is also involved in the provision of logistics and storage services, leasing services and training services, among others. The firm distributes its products mainly in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 9 Aug 1993
- Employees
- 39,296
- Website
- szaccord.com.cn ↗
Leadership
Pay as last reported
- Mr. Yijian WuChairman of the Board, since 2020
- Mr. Guolin GuChief Financial Officer, Chief Compliance Officer, General Counsel, Deputy General ManagerCN¥1.7m
- Mr. Jinxiong LiGeneral Manager, Director, since 2024
- Mr. Chuan LiDeputy General Manager, Secretary of the Board
- Mr. Changbing ChenDeputy General ManagerCN¥1.7m
- Mr. Chu WangDeputy General Manager
- Mr. Honghui ChenIndependent DirectorCN¥250,000
- Mr. Jiannan ChenIndependent Director
- Mr. Shengqun ChenIndependent DirectorCN¥250,000
- Mr. Yongliang OuIndependent DirectorCN¥250,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 71
- Social
- 48
- Governance
- 26
- Women in the workforce
- 83.1%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 39,296 employees support comprehensive pharmaceutical research and development in Shenzhen.
- Main products include antibiotic preparations and cardiovascular drugs for domestic market distribution.
- Headquartered in Shenzhen, Guangdong, the company leverages local industry expertise.
Weaknesses
- Domestic market focus limits international expansion opportunities.
- Logistics and storage services are secondary to core pharmaceutical products.
- Training services do not significantly enhance product competitiveness.
Opportunities
- Growing demand for cardiovascular and respiratory system drugs in China.
- Expansion into pharmaceutical packaging materials and APIs market segments.
- Increased collaboration with domestic healthcare providers.
Threats
- Competition from domestic pharmaceutical firms in China.
- Regulatory changes in the Chinese healthcare sector.
- Economic slowdown affecting domestic healthcare spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.